Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Atrial Fibrillation Clinical Trials

A listing of Atrial Fibrillation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (58) clinical trials

AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation

This is a single centre vanguard phase prospective randomized open label study with blinded outcome adjudication. Patients will be randomized by a central randomization system (1:1) to amiodarone or catheter ablation. Amiodarone will be started at a dose of 400 mg/day. After one month the dose will be lowered to ...

Phase

Additional Linear Ablation Beyond Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation

Pulmonary vein(PV) isolation has become the cornerstone of radiofrequency ablation for AF. However, recent reports have clearly shown that the longer the follow-up period, the lower the success rate with a single ablation procedure. In 5-year follow-up, the mean success rate was only about 45%. The purpose of the study ...

Phase

Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)

This is a randomized, double-blind comparison of two doses of atorvastatin for prevention of post-operative atrial fibrillation.

Phase

A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF

The total AF history should be shorter than 24 months. Symptomatic patients can be included if they have had within the last year at least 2 episodes of documented AF, lasting minimal 30 sec. One episode in the entire history should have lasted more than 48 h, requiring electrical or ...

Phase

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

This is a single site, PI initiated pilot study. This study will enroll up to 75 patients who are clinically indicated for a Left Atrial Appendage (LAA) closure with the commercially available WATCHMAN device. Subjects will be enrolled if they meet study inclusion/exclusion criteria and have a successful LAA closure. ...

Phase

The Effect of Chest Tubes Using Active Clearance Technology on the Incidence of Postoperative Atrial Fibrillation

Data will be collected and stored at the department of surgery of Montreal Heart Institute. Only the principal investigator and study coordinators will have access to the database. The primary analysis will be an intention-to-treat (ITT) analysis comparing the POAF rate in the PleuraFlow group to the POAF rate in ...

Phase

Early Treatment of Atrial Fibrillation for Stroke Prevention Trial

EAST prospectively tests the hypothesis that an early, structured rhythm control therapy based on antiarrhythmic drugs and catheter ablation can prevent atrial fibrillation (AF) related complications in patients with AF when compared to usual care. Patients will be randomized to early therapy or usual care. In the early therapy group, ...

Phase

Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon

Bakground and study rationale: Left atrial (LA) thrombi are found in 2.5 - 18% of subjects with atrial fibrillation (AF) depending on the subject population. Subjects with LA thrombi have a particularly increased risk for cerebral and peripheral embolism. Consequently, oral anticoagulation is recommended in those subjects. Transesophageal echocardiography (TEE) ...

Phase

Low Dose of Diltiazem for Rate Control of Atrial Fibrillation

This study is to show the efficacy and safety of low dose diltiazem for the treatment of atrial fibrillation with rapid ventricular response in emergency room. We will compare the standard dose of diltiazem(0.25mg/kg) with low dose diltiazem(0.1mg/kg)in atrial fibrillation with rapid ventricular response in ED.

Phase

Irbesartan and Adhesion Molecules in AF

Primary Objective: The aim of the study is to assess that blocking the angiotensin II type 1 receptor reduces systemic levels of oxidative stress markers and adhesion molecules by more than 25% compared to placebo in patients with persistent/permanent atrial fibrillation. Primary Target Parameter: The primary target parameter is defined ...

Phase